Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

2.

Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.

Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG; CLARIFY Investigators.

PLoS One. 2015 Apr 27;10(4):e0125164. doi: 10.1371/journal.pone.0125164. eCollection 2015.

3.

Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients.

Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, Ferrari R, Tardif JC, Tendera M, Greenlaw N, Steg PG; CLARIFY Investigators.

PLoS One. 2014 Jul 22;9(7):e102335. doi: 10.1371/journal.pone.0102335. eCollection 2014.

4.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

5.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators.

JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.

PMID:
24825642
6.

Pain and somatic symptoms are sequelae of sexual assault: results of a prospective longitudinal study.

Ulirsch JC, Ballina LE, Soward AC, Rossi C, Hauda W, Holbrook D, Wheeler R, Foley KA, Batts J, Collette R, Goodman E, McLean SA.

Eur J Pain. 2014 Apr;18(4):559-66. doi: 10.1002/j.1532-2149.2013.00395.x. Epub 2013 Sep 10.

PMID:
24019249
7.

Polymorphisms in the glucocorticoid receptor co-chaperone FKBP5 predict persistent musculoskeletal pain after traumatic stress exposure.

Bortsov AV, Smith JE, Diatchenko L, Soward AC, Ulirsch JC, Rossi C, Swor RA, Hauda WE, Peak DA, Jones JS, Holbrook D, Rathlev NK, Foley KA, Lee DC, Collette R, Domeier RM, Hendry PL, McLean SA.

Pain. 2013 Aug;154(8):1419-26. doi: 10.1016/j.pain.2013.04.037. Epub 2013 Apr 26.

8.

μ-Opioid receptor gene A118G polymorphism predicts pain recovery after sexual assault.

Ballina LE, Ulirsch JC, Soward AC, Rossi C, Rotolo S, Linnstaedt SD, Heafner T, Foley KA, Batts J, Collette R, Holbrook D, Zelman S, McLean SA.

J Pain. 2013 Feb;14(2):165-71. doi: 10.1016/j.jpain.2012.10.013. Epub 2012 Dec 20.

PMID:
23260451
9.

Acute severe pain is a common consequence of sexual assault.

McLean SA, Soward AC, Ballina LE, Rossi C, Rotolo S, Wheeler R, Foley KA, Batts J, Casto T, Collette R, Holbrook D, Goodman E, Rauch SA, Liberzon I.

J Pain. 2012 Aug;13(8):736-41. doi: 10.1016/j.jpain.2012.04.008. Epub 2012 Jun 13.

10.

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.

Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators.

Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
22572202
11.

Heart rate and use of beta-blockers in stable outpatients with coronary artery disease.

Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM; CLARIFY Investigators.

PLoS One. 2012;7(5):e36284. doi: 10.1371/journal.pone.0036284. Epub 2012 May 3.

12.

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators.

Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.

PMID:
22402056
13.

Apixaban versus warfarin in patients with atrial fibrillation.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators.

N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.

14.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.

N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

15.

Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study.

Tsoukas G, Anand S, Yang K; CONFIDENCE Investigators.

Am J Cardiovasc Drugs. 2011;11(1):45-55. doi: 10.2165/11587000-000000000-00000.

PMID:
21265582
16.

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada.

Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA; Diabetes Registry to Improve Vascular Events (DRIVE) Investigators.

Can J Cardiol. 2010 Jun-Jul;26(6):297-302.

17.

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.

Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA; Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.

Am J Cardiol. 2009 Sep 15;104(6):798-804. doi: 10.1016/j.amjcard.2009.05.019. Epub 2009 Jul 23.

PMID:
19733714
18.

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups.

Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: Lancet. 2010 Oct 2;376(9747):1146.

PMID:
19716960
19.
20.

Effect of x-ray irradiation on reducing the risk of listeriosis in ready-to-eat vacuum-packaged smoked mullet.

Robertson CB, Andrews LS, Marshall DL, Coggins P, Schilling MW, Martin RE, Collette R.

J Food Prot. 2006 Jul;69(7):1561-4.

PMID:
16865886

Supplemental Content

Loading ...
Support Center